Abstract | OBJECTIVE: DESIGN: A randomized, double-blind study, with a mean follow-up of 15.7 months. SETTING: A 1000-bed teaching hospital in Barcelona, Spain. PATIENTS: Ninety-five patients (68 men and 27 women; mean age, 39 years) diagnosed with brucellosis on the basis of both clinical and serologic findings; 81 of these patients had blood cultures positive for Brucella melitensis. INTERVENTIONS: MAIN OUTCOME MEASURES: Therapeutic failure and relapse during the follow-up period. RESULTS: The mean time to defervescence was 4.2 days for the DR group and 3.2 days for the DS group (P greater than 0.2). The actuarial probability of therapeutic failure or relapse at 12 months of follow-up (Kaplan-Meier) was 14.4% in the DR group and 5.9% in the DS group (difference, 8.5%; 95% Cl, -4.8% to 21.6%; P greater than 0.2). All three patients with spondylitis in the DR group failed therapy compared with one of four patients in the DS group. Excluding patients with spondylitis, the actuarial failure rate was 4.9% and 4.3% in the DR and DS groups, respectively, at 12 months of follow-up (difference, 0.6%; Cl, -8.1% to 9.4%; P greater than 0.2). CONCLUSIONS:
|
Authors | J Ariza, F Gudiol, R Pallares, P F Viladrich, G Rufi, J Corredoira, M R Miravitlles |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 117
Issue 1
Pg. 25-30
(Jul 01 1992)
ISSN: 0003-4819 [Print] United States |
PMID | 1596044
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Doxycycline
- Rifampin
- Streptomycin
|
Topics |
- Adolescent
- Adult
- Aged
- Brucellosis
(drug therapy)
- Child
- Double-Blind Method
- Doxycycline
(therapeutic use)
- Drug Therapy, Combination
(therapeutic use)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Probability
- Recurrence
- Rifampin
(therapeutic use)
- Spondylitis
(drug therapy, microbiology)
- Streptomycin
(therapeutic use)
|